While awaiting an FDA decision for its small molecule revumenib in one form of acute leukemia, Syndax Pharmaceuticals is ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

Johnson & Johnson MedTech has received a go-ahead from the FDA to begin human clinical trials of its Ottava surgical robot, ...

Centessa had recently conducted an interim analysis of a phase 2 study of its drug, called SerpinPC, which is designed to ...

Bayer has become the latest in a long line of drug developers to give up on Huntington’s disease after the German pharma ...

GE HealthCare has tapped imaging provider RadNet for an artificial intelligence collaboration aimed at reshaping the ...

Since the 2023 financing round, Flare’s lead program FX-909 has moved into a phase 1 clinical trial for patients with ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

Almost all cases of ALS and half of frontotemporal dementia (FTD) cases are linked to dysfunction in a protein TDP-43.

23andMe is shutting down its therapeutics development division and plans to seek out buyers to find a new home for its ...

With more than $80 million in hand, the University of Texas MD Anderson Cancer Center has launched its own cell therapy ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...